Browse the evidence

The implementation of MBSAQIP and ERAS protocols has significantly improved the quality of care for all bariatric patients.

Healthcare providers should adopt MBSAQIP and ERAS protocols to enhance patient outcomes.

Collagen supplementation did not change integrated MPS rates compared to the RDA.

Collagen may not be effective for enhancing muscle protein synthesis in older males.

Semaglutide showed a favorable hepatic safety profile with no discontinuations due to liver enzyme elevations.

Semaglutide can be considered safe for liver health in the studied population.

A single-site measure of muscle shape does not adequately capture the effects of exercise training interventions.

Multiple measurement sites should be used to assess training effects accurately.

Obstructive sleep apnea is a common comorbidity in individuals with obesity.

Healthcare providers should be aware of the high prevalence of obstructive sleep apnea in obese patients.

C-reactive protein levels decreased after one year of GLP1-RA treatment.

Monitoring C-reactive protein levels may help assess the effectiveness of GLP1-RA in IBD.

Obesity and its associated conditions significantly impact healthcare systems, life expectancy, and quality of life.

Addressing obesity is crucial for improving healthcare outcomes and quality of life.

New pharmacological treatments for obstructive sleep apnea (OSA) might be effective.

Practitioners should consider new pharmacological options for treating OSA.

Ten proteins were associated with different rates of weight regain, some specifying pathways of chemotaxis and innate immune responses.

Identifying specific proteins may help tailor interventions for weight regain.

Common cardiovascular conditions, such as heart failure with preserved ejection fraction, can be conceptualized as a consequence of accelerated aging.

Understanding the link between aging and heart failure can guide prevention and management strategies.

Genetic predisposition to higher waist-to-hip ratio adjusted for BMI (WHRadjBMI) predicts an increase in waist circumference after weight loss.

Practitioners should consider genetic predisposition when assessing potential waist circumference changes after weight loss.

Remission of diabetes may not be permanent and can result in glycemic relapse over time.

Clinicians should communicate the potential for relapse when discussing remission with patients.

Rapid weight loss induced by semaglutide can lead to noticeable facial volume loss and the appearance of a prematurely aged face, referred to as 'Ozempic face.'

Healthcare providers should be aware of the potential cosmetic implications of semaglutide use for weight loss.

The characteristics of 'Ozempic face' occur in people much younger than what is seen with the natural aging process.

Clinicians should consider age-related factors when assessing patients for semaglutide treatment.

Innovative approaches for nasal delivery of GLP-1 RAs show promising preclinical results.

Practitioners should consider these innovative approaches to enhance the effectiveness of GLP-1 RA delivery.

Contemporary antiretroviral therapy (ART) regimens, particularly integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF), are contributors to weight gain and obesity in PWH.

Clinicians should consider the impact of specific ART regimens on weight management in PWH.

There are fundamental biological principles that raise questions about the therapies for obesity.

Practitioners should be aware of the complexities and potential limitations of obesity therapies.

Muscle tissue protein synthesis and breakdown rates range between 1% and 2% across the day in vivo in humans.

Understanding the turnover rates can help in designing effective training and nutrition strategies.

Novel antidiabetic medications have demonstrated cardiovascular safety and benefits by reducing major adverse cardiac events, improving heart failure, and decreasing CVD-related mortality.

Practitioners should consider novel antidiabetic medications for patients with diabetes and coronary artery disease to improve cardiovascular outcomes.

Metformin shows CVD protective properties for DM-induced atherosclerotic and macrovascular complications.

Metformin should be considered as a first-line treatment for type 2 diabetes to protect against cardiovascular complications.

Insulin monotherapy for T2DM treatment increases the risk of major CV events and deaths from HF compared to metformin.

Practitioners should be cautious when prescribing insulin monotherapy for type 2 diabetes due to increased cardiovascular risks.

Steep weight loss postintervention was associated with increased risk of mortality.

Healthcare providers should be cautious of rapid weight loss in older patients with diabetes.

Obesity promotes the onset of atrial fibrillation (AF) through several pathways.

Understanding these pathways can help in developing targeted interventions for AF in obese patients.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.